2022-01-05 08:23:06 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/68b4f992386bb08378057895bdcebb58 |
Change in substantial holding
|
2022-01-25 08:18:14 |
Immutep Quarterly Activities Report and Appendix 4C |
1 |
https://app.sharelinktechnologies.com/announcement/asx/4a3e6c13c5558961ad5dbd389b23b90d |
Commitments Test Entity - Second Quarter Report
Commitments Test Entity - Second Quarter Activity Report
|
2022-01-31 10:40:35 |
Immutep to present at February Investor Conferences |
0 |
https://app.sharelinktechnologies.com/announcement/asx/6cfa770eaced730dcaecc031b49fe364 |
Company Administration - Other
|
2022-02-02 08:18:06 |
Death of Director Grant Chamberlain |
0 |
https://app.sharelinktechnologies.com/announcement/asx/084abc62060998f4ee955bee9699a68c |
Director Appointment/Resignation
Company Administration - Other
|
2022-02-02 08:25:24 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/2e5993101c8054e77ec6bb305e5790c1 |
Change in substantial holding
|
2022-02-11 11:58:53 |
Australian Patent Granted for Efti with PD-1 Inhibitors |
1 |
https://app.sharelinktechnologies.com/announcement/asx/edb563fd051e9837debff3b4885379be |
|
2022-02-18 08:11:52 |
Immutep Investor Update |
0 |
https://app.sharelinktechnologies.com/announcement/asx/267f049f95b551f6555fd13c25e3f90c |
|
2022-02-18 08:13:23 |
Immutep to present new data from TACTI-002 at ELCC 2022 |
0 |
https://app.sharelinktechnologies.com/announcement/asx/66513e4f533788ddf178350a54217c10 |
Company Administration - Other
|
2022-02-23 18:22:10 |
Half Yearly Report and Accounts |
1 |
https://app.sharelinktechnologies.com/announcement/asx/92b1c65f465fa6fe77e507baec5c2f26 |
Half Year Directors' Statement
Half Year Directors' Report
|
2022-02-24 08:01:59 |
Immutep to Present at Healthcare Investor Conferences |
0 |
https://app.sharelinktechnologies.com/announcement/asx/76769f5f0d4fb408707b1590d2088296 |
Company Administration - Other
|
2022-02-25 08:01:14 |
Appointment of Non-Executive Director |
0 |
https://app.sharelinktechnologies.com/announcement/asx/9eb9d44559534aad168a87d1fcb59112 |
Director Appointment/Resignation
|
2022-02-25 15:42:39 |
Proposed issue of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/f66d1d338b54bac73d9b6bb732167cdf |
|
2022-02-25 15:51:49 |
Initial Director's Interest Notice - Lucy Turnbull |
0 |
https://app.sharelinktechnologies.com/announcement/asx/0a703f16a8f58a7ffbc2ec3bd93af617 |
Initial Director's Interest Notice
|
2022-03-10 08:25:14 |
Immutep receives FDA feedback for Efti development in MBC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/72c93ee8b2c36cf666ea0c3bf8f866dc |
|
2022-03-11 09:26:25 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/59fcab3eceef54e1349b09dac66e288e |
Appendix 2A (Application for Quotation of Securities
|
2022-03-16 08:23:11 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/a14a5fc69fd1d4cc152de3668ab0391f |
Change in substantial holding
|
2022-03-18 15:36:31 |
Japanese patent granted for LAG-3 antibody LAG525 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/859892aa1ec22c3b8950aa30127cc13d |
|
2022-03-18 16:18:12 |
Immutep to present Phase IIb breast cancer data at ESMO 2022 |
0 |
https://app.sharelinktechnologies.com/announcement/asx/dde143d416db2c042f0838caad3833b4 |
Company Administration - Other
|
2022-03-24 08:19:41 |
Immutep announces publication of ELCC 2022 abstract |
1 |
https://app.sharelinktechnologies.com/announcement/asx/f0f17323fab7806b18a36721790fd2e4 |
|
2022-03-30 08:24:37 |
Efti with Keytruda shows encouraging activity in lung cancer |
1 |
https://app.sharelinktechnologies.com/announcement/asx/1f72ae91ee9d37ca42e4773fe4c86fdc |
|
2022-04-08 08:20:08 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/f28728d88f1c5d9c2f554b1e2068570b |
Change in substantial holding
|
2022-04-28 08:22:54 |
Immutep to announce new TACTI-002 data at ASCO 2022 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/6a4018ea9077b4ee73d3af85c1cc5b88 |
|
2022-04-29 08:01:40 |
Quarterly Activities/Appendix 4C Cash Flow Report |
1 |
https://app.sharelinktechnologies.com/announcement/asx/eb046cfd08aec55c17e993159ebe7bce |
Commitments Test Entity - Third Quarter Report
Commitments Test Entity - Third Quarter Activity Report
|
2022-05-04 18:54:48 |
New & significant data from AIPAC phase 2b trial in MBC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/975a52853b5f99d7a10b6f39de1a7736 |
|
2022-05-18 08:17:25 |
Leading Oncologists appointed to Clinical Advisory Board |
0 |
https://app.sharelinktechnologies.com/announcement/asx/6a3553996eb9d9e634e0e7d6ef8e4716 |
Company Administration - Other
|
2022-05-20 08:22:01 |
Immutep to Present at Investor Conferences |
0 |
https://app.sharelinktechnologies.com/announcement/asx/95dfd2154220d2fd26a7b2cde8e3212b |
Company Administration - Other
|
2022-05-24 17:28:19 |
Immutep Corporate Presentation |
0 |
https://app.sharelinktechnologies.com/announcement/asx/60107de955fa3a8bf799dc41d173b819 |
|
2022-05-27 07:34:19 |
Immutep announces publication of ASCO 2022 abstracts |
1 |
https://app.sharelinktechnologies.com/announcement/asx/136e46eeebc2fabb936a003316e758a7 |
|
2022-06-02 08:17:54 |
Immutep webcast for TACTI-002 data presented at ASCO 2022 |
0 |
https://app.sharelinktechnologies.com/announcement/asx/8c2f91990c9b95c8620eb30b667feb03 |
Company Administration - Other
|
2022-06-06 08:20:31 |
Positive ORR in 1st line NSCLC from ph 2 TACTI-002 trial |
1 |
https://app.sharelinktechnologies.com/announcement/asx/beacec2d1caa8a77a7f7de450280b3d1 |
|
2022-06-06 09:04:55 |
Webcast slides for 1st line NSCLC data from TACTI-002 trial |
1 |
https://app.sharelinktechnologies.com/announcement/asx/3f382e286c078a9bc7b763bb792ba094 |
|
2022-06-17 12:38:27 |
Immutep Investor Update |
0 |
https://app.sharelinktechnologies.com/announcement/asx/f447e117c86343cbba172650c0ee8c57 |
|
2022-06-27 09:29:21 |
TACTI-002 lung cancer data to be presented at 2022 WCLC |
0 |
https://app.sharelinktechnologies.com/announcement/asx/740c7d6cffde8f6a4d36acfb372090be |
Company Administration - Other
|
2022-07-06 08:22:07 |
Immutep granted Japanese Patent for IMP761 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/7d50a77fae09d41cef180925833c7f10 |
|
2022-07-14 17:25:24 |
Notification of cessation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/dadc1fb37494b82bffc75a36161221a4 |
Appendix 3H (Notification of cessation of securities)
|
2022-07-28 10:07:04 |
Quarterly Activities/Appendix 4C Cash Flow Report |
1 |
https://app.sharelinktechnologies.com/announcement/asx/c304e265b515f6aa2a41816255c12960 |
Commitments Test Entity - Fourth Quarter Report
Commitments Test Entity - Fourth Quarter Activity Report
|
2022-08-01 07:55:04 |
TACTI-002 2nd line lung cancer data presented at 2022 WCLC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/0c52e482e94f511fac55c5eb1a2d3e10 |
|
2022-08-30 09:43:38 |
Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/4a40aa14896f3ca1a66f0659a2d6e481 |
|
2022-08-31 17:35:27 |
Appendix 4E & 2022 Full Year Statutory Accounts |
1 |
https://app.sharelinktechnologies.com/announcement/asx/cb8e5397db04324fb48e7da8f6d31bf2 |
Full Year Directors' Statement
Full Year Directors' Report
|
2022-09-06 09:21:11 |
New investigator-initiated ph2 trial in Soft Tissue Sarcoma |
1 |
https://app.sharelinktechnologies.com/announcement/asx/d00c9f2272660883c307f038960e0f84 |
|
2022-09-13 08:14:37 |
Immutep Appoints LAG-3 Pioneer Dr Frederic Triebel to Board |
0 |
https://app.sharelinktechnologies.com/announcement/asx/d326a505a1b1d86fc2309da914b0af61 |
Director Appointment/Resignation
|
2022-09-13 08:15:04 |
Initial Director's Interest Notice - Frederic Triebel |
0 |
https://app.sharelinktechnologies.com/announcement/asx/357905d2026802d8270069f114d9bd55 |
Initial Director's Interest Notice
|
2022-09-14 08:14:04 |
Clinical Development Update for Eftilagimod Alpha |
1 |
https://app.sharelinktechnologies.com/announcement/asx/931279e6b68a18b20b1dfcd79ae522c1 |
|
2022-09-21 09:09:05 |
2022 AGM & Key Dates |
0 |
https://app.sharelinktechnologies.com/announcement/asx/e9c26029a04263697805cfc1a2cde699 |
Notice of Meeting - Other
Company Administration - Other
|
2022-09-23 09:09:04 |
Immutep Receives A$2.7 million R&D French Tax Incentive |
1 |
https://app.sharelinktechnologies.com/announcement/asx/0f22d53d2d155d3bfa4c5b4149c06d28 |
|
2022-09-26 08:13:30 |
Immutep to Participate in Two Upcoming Investor Conferences |
0 |
https://app.sharelinktechnologies.com/announcement/asx/408bc859f91089e959daa52d678f156d |
Company Administration - Other
|
2022-09-30 10:47:41 |
Becoming a substantial holder from AEF |
0 |
https://app.sharelinktechnologies.com/announcement/asx/5dcc96f94f75e96cbc0993312ac314ae |
Becoming a substantial holder
|
2022-10-03 11:49:48 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/abfe35d29a14505ccd900fe608d1c710 |
Appendix 2A (Application for Quotation of Securities
|
2022-10-04 09:53:48 |
Fast Track granted by US FDA for Efti in 1st line NSCLC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/e5627a615154229054965736d323bc69 |
|
2022-10-05 17:22:20 |
Change of Director's Interest Notice - F Triebel |
0 |
https://app.sharelinktechnologies.com/announcement/asx/66c3c9397c2d64ab3596d8f6b155fbed |
Change of Director's Interest Notice
|
2022-10-05 17:24:22 |
Change of Director's Interest Notice - M Voigt |
0 |
https://app.sharelinktechnologies.com/announcement/asx/4d2c22bdf30cebebd711d495d70b245b |
Change of Director's Interest Notice
|
2022-10-05 17:24:23 |
Change of Director's Interest Notice - P Meyers |
0 |
https://app.sharelinktechnologies.com/announcement/asx/fdb61f0ed43ca098e94a1621ec370bc4 |
Change of Director's Interest Notice
|
2022-10-06 08:14:18 |
Abstracts accepted for Presentation at SITC 2022 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/2b1d43b0872d9ad7b491ee7abb35d67f |
Company Administration - Other
|
2022-10-06 11:07:05 |
Ceasing to be a substantial shareholder from AEF |
0 |
https://app.sharelinktechnologies.com/announcement/asx/aa9a5304e2ef052830b4b5adcfaceb65 |
Ceasing to be a substantial holder
|
2022-10-13 09:11:09 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/efe6b311f5c66c46976623d9d140d15f |
Appendix 2A (Application for Quotation of Securities
|
2022-10-18 08:08:26 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/180e5c65acdb7b237cfb8a200f0ef3f1 |
Change in substantial holding
|
2022-10-21 14:21:11 |
Annual Report to shareholders |
0 |
https://app.sharelinktechnologies.com/announcement/asx/774e126aab696d4995ca2d552c1d51d1 |
Full Year Directors' Statement
Full Year Directors' Report
|
2022-10-21 14:26:22 |
Appendix 4G and Corporate Governance Statement |
0 |
https://app.sharelinktechnologies.com/announcement/asx/9a2a14c0e21f855243443bb5ae401380 |
|
2022-10-21 14:37:30 |
Notice of Annual General Meeting/Proxy Form |
0 |
https://app.sharelinktechnologies.com/announcement/asx/793b723bb609d43c3504a86072718882 |
Notice of Annual General Meeting
|
2022-10-25 10:49:39 |
Quarterly Activities/Appendix 4C Cash Flow Report |
1 |
https://app.sharelinktechnologies.com/announcement/asx/187d7cc57e9dab8627ae5b80cdf18560 |
Commitments Test Entity - First Quarter Report
Commitments Test Entity - First Quarter Activity Report
|
2022-10-26 09:36:27 |
Independent DMC recommends to continue TACTI-003 as planned |
1 |
https://app.sharelinktechnologies.com/announcement/asx/224ac9ff944310f6193d97dcc87886d4 |
|
2022-10-31 16:07:45 |
Change of Registry Address |
0 |
https://app.sharelinktechnologies.com/announcement/asx/a01e374363e5cc65ca3af1b3a1f5536b |
Details of Share Registry address
|
2022-11-01 07:38:17 |
Annual Report filed on Form 20-F with SEC |
0 |
https://app.sharelinktechnologies.com/announcement/asx/194814f898dc5107e4729ddf5f593d30 |
|
2022-11-02 10:28:21 |
Immutep to Participate in Two Upcoming Investor Conferences |
0 |
https://app.sharelinktechnologies.com/announcement/asx/da3a6319de72a581396f4dedcdba6a75 |
|
2022-11-02 12:45:38 |
Immutep Corporate Presentation |
0 |
https://app.sharelinktechnologies.com/announcement/asx/5fef6efd1493533ce144bd74634b5a6a |
|
2022-11-03 08:33:31 |
Late Breaking Abstract accepted for SITC Oral Presentation |
1 |
https://app.sharelinktechnologies.com/announcement/asx/ccf46a48c4a68cbbca02dc55fadd2581 |
|
2022-11-04 09:08:18 |
Abstract for Efti selected for SITC 2022 Press Conference |
0 |
https://app.sharelinktechnologies.com/announcement/asx/5221cdf354a31c13267296ee686a8c94 |
|
2022-11-09 15:33:31 |
New Patents Granted in Japan and South Korea for Efti |
1 |
https://app.sharelinktechnologies.com/announcement/asx/068fedc0318485784684efa19c01a74b |
|
2022-11-11 08:16:10 |
INSIGHT-003 triple combination data presented at SITC 2022 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/87043c2acccb51885429641907d5f958 |
Company Administration - Other
|
2022-11-11 08:16:17 |
TACTI-002 data presented at SITC for Efti in 1st line NSCLC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/1653d107c6f9fe9dd696cb9ab3d444a6 |
Company Administration - Other
|
2022-11-11 08:16:27 |
Immutep Webcast to discuss clinical data presented at SITC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/734051b89c65d3a04bca9d512b7959ba |
|
2022-11-14 09:18:09 |
Immutep receives A$1 million R&D Tax Incentive |
1 |
https://app.sharelinktechnologies.com/announcement/asx/9f8100325350b45d8cbd7be70dd7521d |
Company Administration - Other
|
2022-11-17 10:58:45 |
Immutep Investor Update |
0 |
https://app.sharelinktechnologies.com/announcement/asx/adc9bce723c89ccbbe5df517e551349c |
|
2022-11-23 08:18:28 |
Immutep AGM 2022 - Chairman's Address |
0 |
https://app.sharelinktechnologies.com/announcement/asx/75157dc9a067bf299a342b0e443223c1 |
Chairman's Address to Shareholders
|
2022-11-23 08:18:31 |
Immutep AGM 2022 - CEO's Presentation |
0 |
https://app.sharelinktechnologies.com/announcement/asx/709b70e60c0f21511d5a43735c607919 |
Chairman's Address to Shareholders
|
2022-11-23 13:01:58 |
Results of Meeting |
0 |
https://app.sharelinktechnologies.com/announcement/asx/447245742f18600a4fc3497aad43744b |
|
2022-11-29 08:14:20 |
Immutep enters 2nd collaboration with Pfizer and Merck KGaA |
1 |
https://app.sharelinktechnologies.com/announcement/asx/469a79dcada667aa3934b29b4108ae7a |
|
2022-12-06 08:59:54 |
GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist |
1 |
https://app.sharelinktechnologies.com/announcement/asx/d4aa1386240d2cf4e7200d271fb29c6e |
|
2022-12-08 08:16:06 |
Commercial Scale in Manufacturing of Efti Achieved |
1 |
https://app.sharelinktechnologies.com/announcement/asx/eea35e07c34d640e588c7f91a26377b6 |
|
2022-12-15 11:09:07 |
Proposed issue of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/adf08ecc0d3ed5ffd9018ebb3d20fddd |
|
2022-12-16 15:25:24 |
Notification regarding unquoted securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/3fd9d44b6cf9cff9ab963e222384b06a |
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
|
2022-12-16 15:26:25 |
Notification regarding unquoted securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/a6bf3d2ed8cd838caf0f585ed68a0069 |
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
|
2022-12-21 12:08:07 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/bbabb563bb8bea25d775dce7836abdb6 |
Appendix 2A (Application for Quotation of Securities
|
2022-12-22 15:54:53 |
Change of Director's Interest Notice - R Howard |
0 |
https://app.sharelinktechnologies.com/announcement/asx/605d8b4d19d316686dda8ef1b9783704 |
Change of Director's Interest Notice
|
2022-12-22 15:56:54 |
Change of Director's Interest Notice - P Meyers |
0 |
https://app.sharelinktechnologies.com/announcement/asx/9c82a5d7553194f767d6ae5fb6879602 |
Change of Director's Interest Notice
|
2022-12-22 15:58:55 |
Change of Director's Interest Notice L Turnbull |
0 |
https://app.sharelinktechnologies.com/announcement/asx/cef5cfb34bdf5ff6deec73d9e5687a2f |
Change of Director's Interest Notice
|
2022-12-23 13:00:50 |
Update on MBC trial design following successful FDA meeting |
1 |
https://app.sharelinktechnologies.com/announcement/asx/9db9c27a2ba4d09307b52a86665cac74 |
|